-
公开(公告)号：WO2012045090A3
公开(公告)日：2012-07-19
申请号：PCT/US2011054654
申请日：2011-10-03
Applicant: VENTIRX PHARMACEUTICALS INC , HERSHBERG ROBERT , COUKOS GEORGE , DIETSCH GREGORY , FACCIABENE ANDREA , MANJARREZ KRISTI , RANDALL TRESSA D
Inventor： HERSHBERG ROBERT , COUKOS GEORGE , DIETSCH GREGORY , FACCIABENE ANDREA , MANJARREZ KRISTI , RANDALL TRESSA D
IPC: A61K31/55 , A61K9/127 , A61K9/48 , A61K31/122 , A61P35/00
CPC classification number: A61K31/55 , A61K9/0019 , A61K9/1271 , A61K31/675 , A61K31/704 , A61K31/7068 , A61K45/06 , A61K47/6951 , B82Y5/00 , A61K2300/00
Abstract: The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.
Abstract translation: 本发明总体上涉及TLR激动剂（优选TLR8激动剂）的制剂，及其在治疗各种疾病（包括用于治疗癌症的联合疗法）中的用途。
-
公开(公告)号：WO2011022508A2
公开(公告)日：2011-02-24
申请号：PCT/US2010045934
申请日：2010-08-18
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC , HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , LYSSIKATOS JOSEPH P , NEWHOUSE BRAD , YANG HONG WOON
Inventor： HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , LYSSIKATOS JOSEPH P , NEWHOUSE BRAD , YANG HONG WOON
IPC: C07D401/14 , A61K31/4025 , A61K31/454 , A61K31/55 , A61P31/00 , A61P35/00 , C07D223/14 , C07D403/10
CPC classification number: A61K31/55 , C07D223/14 , C07D223/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/04 , C07D405/10
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
Abstract translation: 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，感染性疾病，炎性疾病，移植物排斥反应和移植物宿主病。
-
公开(公告)号：WO2012045089A3
公开(公告)日：2012-07-19
申请号：PCT/US2011054652
申请日：2011-10-03
Applicant: VENTIRX PHARMACEUTICALS INC , HERSHBERG ROBERT
Inventor： HERSHBERG ROBERT
CPC classification number: A61K31/55 , A61K9/0043
Abstract: The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis.
Abstract translation: 本发明一般涉及TLR8激动剂VTX-378，用于治疗或预防过敏性疾病，包括过敏性鼻炎。
-
公开(公告)号：WO2012097177A3
公开(公告)日：2012-10-26
申请号：PCT/US2012021116
申请日：2012-01-12
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC , HOWBERT JAMES JEFFRY , HERSHBERG ROBERT
Inventor： HOWBERT JAMES JEFFRY , HERSHBERG ROBERT
IPC: C07D403/10 , A61K31/55 , A61P37/00 , C07D223/14 , C07D403/12
CPC classification number: C07D223/16 , C07D243/14 , C07D401/12 , C07D487/04
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
Abstract translation: 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，纤维化疾病，心血管疾病，感染性疾病，炎症性疾病，移植排斥反应或移植物抗宿主病。
-
公开(公告)号：WO2011022509A3
公开(公告)日：2011-06-16
申请号：PCT/US2010045935
申请日：2010-08-18
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC , HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , DOHERTY GEORGE A , EARY C TODD , GRONEBERG ROBERT D , JONES ZACHARY
Inventor： HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , DOHERTY GEORGE A , EARY C TODD , GRONEBERG ROBERT D , JONES ZACHARY
IPC: C07D403/10 , A61K31/4025 , A61K31/55 , A61P31/00 , A61P35/00 , C07D223/14 , C07D401/14 , C07D403/14
CPC classification number: C07D223/16 , A61K31/4025 , A61K31/55 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll- like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
Abstract translation: 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，感染性疾病，炎性疾病，移植物排斥反应和移植物宿主病。
-
Patent Agency Ranking
公开(公告)号：WO2012097173A3
公开(公告)日：2012-09-20
申请号：PCT/US2012021110
申请日：2012-01-12
Applicant: VENTIRX PHARMACEUTICALS INC , HOWBERT JAMES JEFFRY , HERSHBERG ROBERT
Inventor： HOWBERT JAMES JEFFRY , HERSHBERG ROBERT
IPC: C07D223/16 , A61K31/55 , A61P29/00 , A61P35/00 , C07D403/10
CPC classification number: C07D295/192 , A61K31/55 , C07D223/16 , C07D401/04 , C07D403/10 , C07D413/10 , C07D487/04
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
Abstract translation: 提供了用于调节通过Toll样受体TLR7和/或TLR8的信号转导的组合物和方法。 该组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，纤维化疾病，心血管疾病，传染病，炎症性疾病，移植排斥或移植物抗宿主疾病。
-
公开(公告)号：WO2011133819A3
公开(公告)日：2012-03-08
申请号：PCT/US2011033500
申请日：2011-04-21
Applicant: VENTIRX PHARMACEUTICALS INC , HERSHBERG ROBERT
Inventor： HERSHBERG ROBERT
IPC: A61K31/55 , A61K39/395 , A61P35/00 , A61P35/02
CPC classification number: A61K31/55 , A61K39/39 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/2887 , C07K16/3046 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/732
Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
Abstract translation: 本申请涉及在接受治疗性单克隆抗体治疗的受试者中增加抗体依赖性细胞毒性的方法。 在一些实施方案中，提供了用于施用以治疗有需要的受试者与ADCC增强子分子结合的治疗性抗体的方法。
-
公开(公告)号：CA2797182C
公开(公告)日：2019-02-12
申请号：CA2797182
申请日：2011-04-21
Applicant: VENTIRX PHARMACEUTICALS INC
Inventor： HERSHBERG ROBERT
IPC: A61K31/55 , A61K39/395 , A61P35/00 , A61P35/02
Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
-
公开(公告)号：CA2771484C
公开(公告)日：2019-01-15
申请号：CA2771484
申请日：2010-08-18
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC
Inventor： HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , DOHERTY GEORGE A , EARY C TODD , GRONEBERG ROBERT D , JONES ZACHARY
IPC: C07D403/10 , A61K31/4025 , A61K31/55 , A61P31/00 , A61P35/00 , C07D223/14 , C07D401/14 , C07D403/14
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll- like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease. The provided compositions include (see above formula)
-
公开(公告)号：PL2467377T3
公开(公告)日：2017-10-31
申请号：PL10810563
申请日：2010-08-18
Applicant: VENTIRX PHARMACEUTICALS INC , ARRAY BIOPHARMA INC
Inventor： HOWBERT JAMES JEFFRY , DIETSCH GREGORY , HERSHBERG ROBERT , BURGESS LAURENCE E , LYSSIKATOS JOSEPH P , NEWHOUSE BRAD , YANG HONG WOON
IPC: C07D401/14 , A61K31/4025 , A61K31/454 , A61K31/55 , A61P31/00 , A61P35/00 , C07D223/14 , C07D403/10
-
-
-
-
-
-
-
-
-
Search Results
78
records
(took 0.023 seconds)
